Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Illuminate-2: Neoadjuvant Toripalimab + Chemotherapy in OSCC
NCT05125055Phase 3Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Oct 2021
- Primary completion
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of toripalimab in oral squamous cell carcinoma (OSCC) (2 arms), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Major Pathologic Response at 3 months. Started Oct 2021; status: recruiting.
02
Drugs
toripalimab
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT05125055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05125055.